Holen Sie sich die Stockscreener-App
209.11
1.24%
1.79
Revolution Medicines Inc Aktie (RVMD) Neueste Nachrichten
Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial - The Manila Times
Revolution Medicine’s $39,800-Monthly Cancer Drug Puts Access In Focus — CEO Goldsmith Expects Insurers To Move ‘Swiftly’ To Provide Coverage - Stocktwits
Revolution Medicines (RVMD) Wins FDA Nod While Cancer Study Lands In Leading Journal - Yahoo Finance
Revolution Med (RVMD) Priced Rasonque at $39,800 per 30-Day Supply. Can Access Match the Clinical Breakthrough? - Yahoo Finance
Revolution Medicines Got Its Breakthrough—What Moves It Next? - MarketBeat
Revolution’s Rasonque Shows Promise In Lung Cancer - insights.citeline.com
Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue? - Yahoo Finance
$100 Invested In Revolution Medicines 5 Years Ago Would Be Worth This Much Today - Benzinga
Revolution Medicines(RVMD.US) Director Sells US$11.38 Million in Common Stock - Moomoo
RVMD Shares React as Phase 1/2 RASONQUE Data Published in NEJM - GuruFocus
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer - The Manila Times
Revolution Medicines Announces NEJM Publication of Phase 1/2 RASONQUE Data Supporting Ongoing Phase 3 RASolve 301 Trial in RAS Mutant NSCLC - Quiver Quantitative
An experimental lung cancer drug held disease in check for 89% of patients in one group. - Stock Titan
Revolution Medicines (RVMD) insider sale under preset trading plan - Stock Titan
Challenging Convention to Solve the Hardest Problems in Medicine – Revolution Medicines - Oncodaily
Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals - BioSpace
Revolution Medicines: Benefit Vs Reality Compared To Peer Therapeutics (NASDAQ:RVMD) - Seeking Alpha
Revolution Medicines Enters Lease Agreements for New Headquarters in Redwood City - marketscreener.com
What Revolution Medicines (RVMD)'s RASONQUE Pancreatic Cancer Focus Means For Shareholders - webull.com
New pancreatic cancer pill priced at $480,000 per year - KTLA
Revolution Medicines (NASDAQ: RVMD) trust moves to sell 73,090 shares - Stock Titan
Revolution’s newly approved drug doubles pancreatic cancer survival time - Mugglehead Investment Magazine
Revolution Medicines: Strong Buy RASONQUE FDA Approval And Zoldonrasib PDAC Expansions - Seeking Alpha
StockWatch: Revolution Shares Stay Flat Despite Historic FDA Approval of Oral Pancreatic Cancer Therapy - Genetic Engineering and Biotechnology News
Revolution Medicines: RASONQUE's FDA Approval Portends A New Oncology Titan (NASDAQ:RVMD) - Seeking Alpha
Revolution Medicines Wins FDA Approval for RASONQUE in Metastatic Pancreatic Cancer - TradingView
Revolution Medicines (RVMD) Falls as Investors Appear to Take Profits After FDA Approval - Quiver Quantitative
Revolution Medicines Stock Trades Higher Following Landmark FDA Approval for Pancreatic Cancer Drug - Benzinga
Revolution Medicines stock hits all-time high at 220.8 USD - Investing.com
Revolution Medicines to Charge $39,800 a Month for Pancreatic Cancer Drug, Bloomberg Reports - marketscreener.com
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer - Barchart.com
Revolution Medicines gets FDA nod for targeted pancreatic cancer drug - Yahoo! Finance Canada
Revolution Medicines (RVMD) Gains FDA Approval for Rasonque, Sha - GuruFocus
US FDA approves Revolution Medicines' pancreatic cancer drug - marketscreener.com
Revolution Medicines (RVMD) CEO trades stock under preset 10b5-1 plan - Stock Titan
Revolution Medicines nears lease for 700,000-square-foot Redwood City campus - The Business Journals
Revolution Medicines (NASDAQ: RVMD) trust plans 3,000-share Rule 144 sale - Stock Titan
Revolution Medicines (NASDAQ: RVMD) director plans August stock sale after June $1.6M trade - Stock Titan
Revolution Medicines (NASDAQ: RVMD) holder eyes $16M stock sale - Stock Titan
RVMD Maintained by Bernstein -- Price Target Raised to $179 - GuruFocus
REVOLUTION MEDICINES, INC. : BERNSTEIN RAISES TARGET PRICE TO $179 FROM $151 - Bitget
Revolution Medicines (NASDAQ: RVMD) trust to sell 3,000 shares under Rule 144 - Stock Titan
Price to sales forward of Revolution Medicines, Inc. – NASDAQ:RVMDW - TradingView
Enterprise value to revenue forward of Revolution Medicines, Inc. – NASDAQ:RVMDW - TradingView
Why Revolution Medicines May Be Big Pharma’s Next Takeover Target - AOL.com
Breakthrough Pancreatic Cancer Drug Maker Builds on Illinois Research Roots - Carle Illinois College of Medicine
Price to book forward of Revolution Medicines, Inc. – NASDAQ:RVMDW - TradingView
Revolution (RVMDW) Price and Levels: Advances 4.09% to $12.59 in Latest Trading; Technical Focus: the $11.96 to $13.22 Range Remains in Focus in the Available RecordBollinger Walk - Vinanet
Why Revolution Medicines (RVMD) Stock Is Up Today - Quiver Quantitative
Revolution Medicines stock hits all-time high at 208.77 USD - Investing.com
Revolution Medicines stock hits all-time high at 208.77 USD By Investing.com - Investing.com Australia
Corcept, Revolution Medicines lead ten large-cap healthcare stocks surging in 2026 (XLV:NYSEARCA) - Seeking Alpha
Revolution Medicines, Inc. (RVMD) Stock Analysis: Exploring Growth Potential with RAS-Targeted Therapies - DirectorsTalk Interviews
State of Wyoming Buys Shares of 9,446 Revolution Medicines, Inc. $RVMD - MarketBeat
S&CO Inc. Invests $6.40 Million in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines (MEX:RVMD) Shiller PE Ratio : (As of Aug. 16, 2026) - GuruFocus
Revolution Medicines Inc Stock Baskets - GuruFocus
Is BeOne Medicines AG (ONC) Deal With Revolution Medicines (RVMD) a Win-Win for Both Companies? - Yahoo Finance
Baker Bros. Advisors (RVMD) discloses 11.4M-share position in Revolution Medicines - Stock Titan
Farallon funds disclose 13.6M-share RVMD stake in Schedule 13G/A filing - Stock Titan
Revolution Medicines (RVMD): Janus Henderson discloses 5.1% beneficial stake - Stock Titan
ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits
Revolution Medicines (RVMD) Q2 2026 Earnings Call Transcript - AOL.com
(RVMD) Volatility Zones as Tactical Triggers - Stock Traders Daily
Revolution and BeOne Meds enter research pact - thepharmaletter.com
Revolution Medicines hits $44B market cap with breakthrough RAS cancer drugs, attracting big pharma interest. - Pluang
1.08%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):